Literature DB >> 21448763

The use of family history questionnaires: an examination of genetic risk estimates and genetic testing eligibility in the non-responder population.

Susan Randall Armel1, Kara Hitchman, Kathryn Millar, Laura Zahavich, Rochelle Demsky, Joan Murphy, Barry Rosen.   

Abstract

The use of mailed family history questionnaires (FHQs) has previously been established to be an effective method for obtaining family history information for the triage of patients for genetic counseling and genetic testing of hereditary breast and ovarian cancer syndrome; yet only 53% of patients complete their FHQ within 6 months from the date of mailing (Armel et al. Journal of Genetic Counseling, 18(4):366-378, 2009). Although literature exists evaluating why women may not attend genetic counseling, no data are currently available examining genetic risk or genetic testing eligibility in the population of patients not returning their FHQ (non-responders). Concern exists that if non-responders are not followed-up for the purpose of triage for genetic counseling, individuals at high-risk for a hereditary cancer syndrome may be missed. This article explores the demographics of the non-responder population to assess genetic risk estimates for mutations in the BRCA1 and BRCA2 genes and genetic testing eligibility as compared to a responder population of patients who completed a mailed FHQ. A total of 430 pedigrees were obtained, 215 from non-responders and 215 from responders. Results of this study indicate that 69% of non-responders were either unreachable by telephone (42%), declined an appointment (19%), or were previously seen in another center for a genetic counseling visit (8%). Additionally, results indicate that non-responders are less likely to be eligible for genetic testing (40%) as compared to responders (57%) (p = 0.0004). Together these data shed light on a population of patients for which limited information exists and suggest that we question how and to what extent clinics should pursue non-responders, particularly in light of global reductions in health care funding.

Entities:  

Mesh:

Year:  2011        PMID: 21448763     DOI: 10.1007/s10897-011-9359-8

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  24 in total

1.  Factors associated with decisions about clinical BRCA1/2 testing.

Authors:  K Armstrong; K Calzone; J Stopfer; G Fitzgerald; J Coyne; B Weber
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-11       Impact factor: 4.254

2.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

3.  Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network.

Authors:  C Julian-Reynier; H Sobol; C Sévilla; C Noguès; P Bourret
Journal:  Psychooncology       Date:  2000 Nov-Dec       Impact factor: 3.894

4.  Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.

Authors:  D F Easton; L Steele; P Fields; W Ormiston; D Averill; P A Daly; R McManus; S L Neuhausen; D Ford; R Wooster; L A Cannon-Albright; M R Stratton; D E Goldgar
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

5.  Factors influencing patients' decisions to decline cancer genetic counseling services.

Authors:  K P Geer; M E Ropka; W F Cohn; S M Jones; S Miesfeldt
Journal:  J Genet Couns       Date:  2001-02       Impact factor: 2.537

6.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

7.  Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort.

Authors:  C Foster; D G R Evans; R Eeles; D Eccles; S Ashley; L Brooks; T Cole; J Cook; R Davidson; H Gregory; J Mackay; P J Morrison; M Watson
Journal:  Genet Test       Date:  2004

8.  The effectiveness of family history questionnaires in cancer genetic counseling.

Authors:  Susan Randall Armel; Jeanna McCuaig; Amy Finch; Rochelle Demsky; Tony Panzarella; Joan Murphy; Barry Rosen
Journal:  J Genet Couns       Date:  2009-05-21       Impact factor: 2.537

9.  Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer.

Authors:  Kathryn J Schlich-Bakker; Herman F J ten Kroode; Carla C Wárlám-Rodenhuis; Jan van den Bout; Margreet G E M Ausems
Journal:  Genet Med       Date:  2007-11       Impact factor: 8.822

10.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

View more
  3 in total

1.  Cancer family history triage: a key step in the decision to offer screening and genetic testing.

Authors:  Paul Brennan; Oonagh Claber; Tracey Brennan
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

2.  All in the Family: Barriers and Motivators to the Use of Cancer Family History Questionnaires and the Impact on Attendance Rates.

Authors:  Susan Randall Armel; Jeanna McCuaig; Nicole Gojska; Rochelle Demsky; Manjula Maganti; Joan Murphy; Barry Rosen
Journal:  J Genet Couns       Date:  2015-01-07       Impact factor: 2.537

3.  Reading between the lines: a comparison of responders and non-responders to a family history questionnaire and implications for cancer genetic counselling.

Authors:  Julia H Appleby-Tagoe; William D Foulkes; Laura Palma
Journal:  J Genet Couns       Date:  2011-08-16       Impact factor: 2.537

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.